Why Shares of Theravance Inc Dropped 49% in September

Bad news related to a clinical trial sent shareholders to the exits. Is this sell-off a buying opportunity?

Brian Feroldi

(TMFTypeoh)

Oct 25, 2015 at 3:03PM

Shares of Theravance (UNKNOWN:THRX.DL), a healthcare royalty management company for a focus on respiratory products, were down big during September after the company and its partner GlaxoSmithKline PLC (NYSE:GSK) released disappointing clinical news.

Are the shares a buy after the fall? See the presentation below for details.

Author

Brian Feroldi

(TMFTypeoh)

Brian Feroldi has been covering the healthcare and technology industries for the Motley Fool since 2015. Brian's investing goal is to find the highest quality companies that he can find, buy them, and then to sit back and let compounding work its magic. See all of his articles here and make sure you follow him on Twitter. Follow @brianferoldi

Article Info

Oct 25, 2015 at 3:03PM
Health Care

Author

Article Info

Stocks

THRX.DL

Theravance

UNKNOWN:THRX.DL

GSK

GlaxoSmithKline

NYSE:GSK

IBB

iShares NASDAQ Biotechnology Index

NASDAQ:IBB

Related Articles

Compare Brokers